MedPath

Celecoxib

Generic Name
Celecoxib
Brand Names
Celebrex, Elyxyb, Seglentis
Drug Type
Small Molecule
Chemical Formula
C17H14F3N3O2S
CAS Number
169590-42-5
Unique Ingredient Identifier
JCX84Q7J1L
Background

Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.

Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.

Indication

Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.

It may be also be used to treat acute pain from various sources, juvenile rheumatoid arthritis in children over 2, ankylosing spondylitis, and primary dysmenorrhea.

Celecoxib, in combination with tramadol, is indicated for the management of acute pain in adults severe enough to require an opioid analgesic and in whom alternative treatments are inadequate.

Associated Conditions
Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain
Associated Therapies
-

Multimodal Pain Management After Robotic-Assisted Total Laparoscopic Hysterectomy

Phase 3
Completed
Conditions
Pain, Postoperative
Interventions
Drug: Gabapentin
Drug: Hydromorphone
Drug: Acetaminophen
Drug: Celecoxib
Drug: Ketorolac
Procedure: Paracervical block with ropivacaine
Procedure: Local anesthetic injection with ropivacaine at abdominal laparoscopic port sites
Drug: Oxycodone
First Posted Date
2020-06-11
Last Posted Date
2023-08-01
Lead Sponsor
State University of New York at Buffalo
Target Recruit Count
68
Registration Number
NCT04429022
Locations
🇺🇸

Millard Fillmore Suburban Hospital, Williamsville, New York, United States

Perioperative Analgesia on Postoperative Opioid Usage and Pain Control in H&N Cancer Surgery

Phase 3
Terminated
Conditions
Postoperative Pain Control
Opioid Consumption
Interventions
First Posted Date
2019-11-25
Last Posted Date
2024-11-12
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
30
Registration Number
NCT04176419
Locations
🇺🇸

Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer

Phase 2
Suspended
Conditions
Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Oral Cavity Carcinoma
Recurrent Hypopharyngeal Carcinoma
Recurrent Nasal Cavity and Paranasal Sinus Carcinoma
Stage III Laryngeal Cancer AJCC v8
Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Stage IVA Laryngeal Cancer AJCC v8
Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Recurrent Oral Cavity Carcinoma
Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Drug: Celecoxib
Other: Placebo
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
First Posted Date
2019-11-14
Last Posted Date
2024-02-13
Lead Sponsor
University of Utah
Target Recruit Count
60
Registration Number
NCT04162873
Locations
🇺🇸

Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States

Effect of Celecoxib on Postoperative Analgesia and Disease Severity in AERD Patients with CRS

Phase 4
Active, not recruiting
Conditions
Chronic Rhinosinusitis with Nasal Polyps
Aspirin-exacerbated Respiratory Disease
Interventions
Drug: Placebo
Drug: Celecoxib
First Posted Date
2019-10-31
Last Posted Date
2024-10-29
Lead Sponsor
Lawson Health Research Institute
Target Recruit Count
44
Registration Number
NCT04147013
Locations
🇨🇦

St. Joseph's Healthcare London, London, Ontario, Canada

🇸🇦

King Abdulaziz University Hospital, Jeddah, Saudi Arabia

Individualizing Anti-Inflammatory Medications for Adults With Axial Spondyloarthritis: A Series of N-of 1 Trials

Phase 2
Completed
Conditions
Axial Spondyloarthritis
Interventions
First Posted Date
2019-10-03
Last Posted Date
2023-12-05
Lead Sponsor
The University of Texas Health Science Center, Houston
Target Recruit Count
42
Registration Number
NCT04115098
Locations
🇺🇸

The University of Texas Health Science Center at Houston, Houston, Texas, United States

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Phase 2
Recruiting
Conditions
HLA-A2 Positive Cells Present
Refractory Melanoma
Interventions
Biological: Alpha-type-1 Polarized Dendritic Cells
Drug: Celecoxib
Drug: PD-1 Ligand Inhibitor
Drug: PD1 Inhibitor
Biological: Recombinant Interferon Alfa-2b
Drug: Rintatolimod
First Posted Date
2019-09-18
Last Posted Date
2024-08-02
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
24
Registration Number
NCT04093323
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

Phase 1
Completed
Conditions
HER2/Neu Negative
Progesterone Receptor Negative
Prognostic Stage IB Breast Cancer AJCC v8
Prognostic Stage IIA Breast Cancer AJCC v8
Anatomic Stage IB Breast Cancer AJCC v8
Anatomic Stage IIB Breast Cancer AJCC v8
Prognostic Stage II Breast Cancer AJCC v8
Prognostic Stage IA Breast Cancer AJCC v8
Triple-Negative Breast Carcinoma
Anatomic Stage IIA Breast Cancer AJCC v8
Interventions
First Posted Date
2019-09-09
Last Posted Date
2023-09-11
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
9
Registration Number
NCT04081389
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

Phase 1
Active, not recruiting
Conditions
Myeloproliferative Neoplasm
Interventions
First Posted Date
2019-08-01
Last Posted Date
2024-06-18
Lead Sponsor
AbbVie
Target Recruit Count
85
Registration Number
NCT04041050
Locations
🇺🇸

Providence - St. Jude Medical Center /ID# 242558, Fullerton, California, United States

🇺🇸

Moores Cancer Center at UC San Diego /ID# 229584, La Jolla, California, United States

🇺🇸

City of Hope /ID# 239769, Duarte, California, United States

and more 39 locations

A Multimodal Analgesia Protocol Adapted for Ambulatory Surgery

First Posted Date
2019-07-11
Last Posted Date
2024-07-08
Lead Sponsor
University of Utah
Target Recruit Count
100
Registration Number
NCT04015908
Locations
🇺🇸

University of Utah, Salt Lake City, Utah, United States

Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen

Phase 3
Completed
Conditions
Analgesia
Interventions
Drug: HTX-011
Drug: Ibuprofen
Drug: Acetaminophen
Drug: +/- Bupivacaine HCl
Drug: Celecoxib
Device: Luer Lock Applicator
First Posted Date
2019-06-05
Last Posted Date
2023-08-31
Lead Sponsor
Heron Therapeutics
Target Recruit Count
116
Registration Number
NCT03974932
Locations
🇺🇸

Endeavor Clinical Trials, LLC., San Antonio, Texas, United States

🇺🇸

Helen Keller Hospital, Sheffield, Alabama, United States

🇺🇸

Phoenix Clinical Research, LLC, Tamarac, Florida, United States

and more 3 locations
© Copyright 2025. All Rights Reserved by MedPath